Related Experiment Video
Updated: Sep 4, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
Published on: April 13, 2015
Telomerase and cancer: time to move from a promising target to a clinical reality
W N Keith1, T R Jeffry Evans, R M Glasspool
1CRC Department of Medical Oncology, University of Glasgow, CRC Beatson Laboratories, Garscube Estate, Switchback Road, Glasgow G61 1BD, UK. n.keith@beatson.gla.ac.uk
Abstract:
The past 25 years have seen unparalleled advances in our understanding of the molecular basis of cancer. As a result, novel molecular targets have been identified that provide great potential for the development of new cancer diagnostics and therapies. Four key features of cancer cells distinguish them from their normal counterparts: loss of cell-cycle regulation, loss of control over invasion and metastasis, failure of apoptotic mechanisms, and bypass of senescence. This review examines our understanding of the bypass of senescence and the process of immortalization during carcinogenesis. In addition, the realistic opportunities for telomerase in cancer diagnostics and the challenges faced in clinical trial design for telomerase therapeutics are discussed.
Insights
Cancer cells evade senescence, a key aging process, contributing to uncontrolled growth and immortalization. This review explores senescence bypass, telomerase
Area of Science:
- Molecular biology of cancer
- Cellular senescence and immortalization
- Cancer diagnostics and therapeutics
Background:
- Significant progress in understanding cancer's molecular underpinnings over the last 25 years.
- Identification of novel molecular targets for cancer diagnostics and therapies.
- Four hallmarks of cancer: cell-cycle dysregulation, invasion/metastasis, apoptosis evasion, and senescence bypass.
Purpose of the Study:
- To review the current understanding of senescence bypass and immortalization in carcinogenesis.
- To discuss the potential of telomerase in cancer diagnostics.
- To examine challenges in designing clinical trials for telomerase-based cancer therapies.
Main Methods:
- Review of existing scientific literature on cancer biology, senescence, and telomerase.
- Analysis of molecular mechanisms underlying cancer cell hallmarks.
- Discussion of clinical trial design principles for targeted therapies.
Main Results:
- Senescence bypass and cellular immortalization are critical processes in cancer development.
- Telomerase presents realistic opportunities for cancer diagnostics.
- Significant challenges exist in the clinical application of telomerase therapeutics.
Conclusions:
- Understanding senescence bypass is crucial for developing new cancer treatments.
- Telomerase holds promise for cancer detection and therapy, but clinical translation requires careful consideration of trial design.
- Continued research into cancer's molecular basis will drive innovation in diagnostics and therapeutics.
More Related Videos
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
09:13Generation of Cancer Cell Clones to Visualize Telomeric Repeat-containing RNA TERRA Expressed from a Single Telomere in Living Cells
Published on: January 17, 2019
Related Concept Videos
Telomeres and Telomerase
Replicative Cell Senescence
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...